[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640027":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":11,"centralContacts":38,"locations":44,"responsibleParty":68,"collaborators":11,"id":70,"slug":11,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":11,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":11,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Kupando GmbH","INDUSTRY",[8,14,17,20,23,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose level 1","EXPERIMENTAL",null,[13],"Drug: KUP-101A",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Dose level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Dose level 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Dose level 5",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Dose level 6",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Dose level 7",[13],[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"DRUG","KUP-101A","Intravenous infusion of KUP-101A",[9,15,18,21,24,27,30],[39],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Clinical Operations","CONTACT","+49 30 52 00 58 60 20","clinicaltrials@kupando.com",[45,58],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":11},"Universitätsklinikum Würzburg","RECRUITING","Würzburg","Bavaria","97080","Germany",{"type":53,"coordinates":54},"Point",[55,56],9.95121,49.79391,{"lat":56,"lon":55},{"facility":59,"status":47,"city":60,"state":61,"zip":62,"country":51,"cosmosGeoPoint":63,"geoPoint":67,"contacts":11},"Fachklinik Hornheide","Münster","North Rhine-Westphalia","48157",{"type":53,"coordinates":64},[65,66],7.62571,51.96236,{"lat":66,"lon":65},{"type":69,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640027",false,"NCT07600476","A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed cancer with evidence of advanced disease for which no other standard treatment is available\n* ECOG Performance status of 0 to 2\n* Adequate hematological, renal, and hepatic organ function\n\nExclusion Criteria:\n\n* Previous systemic treatment with TLR agonists, with the exception of TLR agonists used as vaccine adjuvants.\n* Known additional malignancy that is progressing or requires active treatment\n* Diagnosis of immunodeficiency\n* Active autoimmune disease not caused by prior anticancer treatment that required systemic immunosuppressive treatment in the past 2 years\n* Active autoimmune disease caused by prior anticancer treatment, unless currently controlled by replacement therapy only.\n* Any kind of leukemia\n* Previously received an organ transplant (other than corneal transplants) or hematopoietic stem cell transplantation\n* Known active central nervous system metastases and\u002For carcinomatous meningitis\n* Cerebral vascular event within 6 months before Screening\n* Unstable cardiopulmonary status defined by uncontrolled congestive heart failure of New York Heart Association Grade III or IV, unstable angina, or myocardial infarction within 6 months before Screening\n* High grade ocular disease such as uncontrolled glaucoma","ALL","18 Years",{"count":78,"type":79},21,"ESTIMATED","INTERVENTIONAL",[82],"PHASE1","The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.",[85,86,87,88,89],"Cutaneous Melanoma","Mucosal Melanoma","Cutaneous Squamous Cell Carcinoma (CSCC)","Merkel Cell Carcinoma of Skin","Basal Cell Carcinoma of Skin",[91,92,93,94,95,96],"TLR4 agonist","TLR7 agonist","TLR4\u002F7 agonist","skin cancer","innate immunity","immunotherapy","2026-05-13",{"date":99,"type":100},"2026-05-20","ACTUAL",{"date":102,"type":79},"2026-04",{"date":104,"type":79},"2028-12",{"name":5,"class":6},2]